Efficacy and safety of serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRI) for children and adolescents with anxiety disorders: a systematic review and meta-analysis

References

• Costello EJ, Egger H, Angold A. 10-year research update review: the epidemiology of child and adolescent psychiatric disorders: I. Methods and public health burden. J Am Acad Child Adolesc Psychiatry. 2005;44(10):972–986.
   PubMed Web of Science ®Google Scholar
• Ford T, Goodman R, Meltzer H. The British child and adolescent mental health survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(10):1203–1211.
   PubMed Web of Science ®Google Scholar
• Ezpeleta L, Keeler G, Erkanli A, et al. Epidemiology of psychiatric disability in childhood and adolescence. J Child Psychol Psychiatry. 2001;42(7):901–914.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62(6):593–602.
   PubMed Web of Science ®Google Scholar
• Beesdo K, Knappe S, Pine D. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin North Am. 2009;32(3):483–524.
   PubMed Web of Science ®Google Scholar
• Pine DS, Helfinstein SM, Bar-Haim Y, et al. Challenges in developing novel treatments for childhood disorders: lessons from research on anxiety. Neuropsychopharmacology. 2009;34(1):213–228.
   PubMed Web of Science ®Google Scholar
• Langley AK, Falk A, Peris T, et al. The child anxiety impact scale: examining parent- and child-reported impairment in child anxiety disorders. J Clin Child Adolesc Psychol. 2014;43(4):579–591.
   PubMed Web of Science ®Google Scholar
• Pine DS, Cohen P, Gurley D, et al. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry. 1998;55(1):56–64.
   PubMed Web of Science ®Google Scholar
• Connolly SD, Bernstein GA, Work Group on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(2):267–283.
   PubMed Web of Science ®Google Scholar
• Costello EJ, Mustillo S, Erkanli A, et al. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry. 2003;60(8):837–844.
   PubMed Web of Science ®Google Scholar
• Woodward LJ, Fergusson DM. Fergusson DMJJotAAoC, psychiatry A. Life course outcomes of young people with anxiety disorders in adolescence. J Am Acad Child Adolesc Psychiatry. 2001;40(9):1086–1093.
   PubMed Web of Science ®Google Scholar
• Foley DL, Goldston DB, Costello EJ, et al. Proximal psychiatric risk factors for suicidality in youth: the great smoky mountains study. Arch Gen Psychiatry. 2006;63(9):1017–1024.
   PubMed Web of Science ®Google Scholar
• Jacobson CM, Muehlenkamp JJ, Miller AL, et al. Psychiatric impairment among adolescents engaging in different types of deliberate self-harm. J Clin Child Adolesc Psychol. 2008;37(2):363–375.
   PubMed Web of Science ®Google Scholar
• Socialstyrelsen. Nationella riktlinjer för vård vid depression och ångestsyndrom – stöd för styrning och ledning [the Swedish national clinical guidelines for anxiety and affective disorders: Support for management and administration]. Stockholm: Socialstyrelsen; 2017.
   Google Scholar
• Garland EJ, Kutcher S, Virani A, et al. Update on the use of SSRIs and SNRIs with children and adolescents in clinical practice. J Canadian Acad Child Adolesc Psychiatry. 2016;25(1):4.
   PubMedGoogle Scholar
• Walkup JT, Labellarte MJ, Riddle MA, et al. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;344(17):1279–1285.
   PubMed Web of Science ®Google Scholar
• Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(4):415–423.
   PubMed Web of Science ®Google Scholar
• March JS, Entusah AR, Rynn M, et al. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007;62(10):1149–1154.
   PubMed Web of Science ®Google Scholar
• Rynn MA, Walkup JT, Compton SN, et al. Child/adolescent anxiety multimodal study: evaluating safety. J Am Acad Child Adolesc Psychiatry. 2015;54(3):180–190.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Mills JA, Sauley BA, et al. The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a Meta-analysis. J Am Acad Child Adolesc Psychiatry. 2018;57(4):235–244.
   PubMed Web of Science ®Google Scholar
• Carlson G. Psychology A. Early onset bipolar disorder: clinical and research considerations. J Clin Child Adolesc Psychol. 2005;34(2):333–343.
   PubMed Web of Science ®Google Scholar
• Go FS, Malley EE, Birmaher B, et al. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 1998;8(1):73–80.
   PubMed Web of Science ®Google Scholar
• Guilé J-M. Psychopharmacology a. Sertraline-induced behavioral activation during the treatment of an adolescent with major depression. J Child Adolesc Psychopharmacol. 1996;6(4):281–285.
   PubMed Web of Science ®Google Scholar
• Reid JM, Storch EA, Murphy TK, et al. Development and psychometric evaluation of the treatment-emergent activation and suicidality assessment profile. Child Youth Care Forum. 2010;39:113–124.
   Google Scholar
• Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753–2766.
   PubMed Web of Science ®Google Scholar
• Locher C, Koechlin H, Zion SR, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and Meta-analysis. JAMA Psychiatry. 2017;74(10):1011–1020.
   PubMed Web of Science ®Google Scholar
• Goodman WK, Murphy TK, Storch EAJP. Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology (Berl). 2007;191(1):87–96.
   PubMed Web of Science ®Google Scholar
• Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a Meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–1696.
   PubMed Web of Science ®Google Scholar
• Storebø OJ, Ramstad E, Krogh HB, Cochrane Developmental, Psychosocial and Learning Problems Group, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;2016(11).
   Google Scholar
• Wang Z, Whiteside SP, Sim L, et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and Meta-analysis. JAMA Pediatr. 2017;171(11):1049–1056.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Welge JA, Wehry AM, et al. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32(3):149–157.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Geracioti L, Rajdev N, et al. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057–1070.
   PubMed Web of Science ®Google Scholar
• Ipser JC, Stein DJ, Hawkridge S, et al. Cochrane review: pharmacotherapy for anxiety disorders in children and adolescents. Evid-Based Child Health. 2010;5(2):555–628.
   Google Scholar
• Luft MJ, Lamy M, DelBello MP, et al. Antidepressant-Induced activation in children and adolescents: Risk, recognition and management. Curr Probl Pediatr Adolesc Health Care. 2018;48(2):50–62.
   PubMed Web of Science ®Google Scholar
• Reinblatt SP, Dosreis S, Walkup JT, et al. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents. J Child Adolesc Psychopharmacol. 2009;19(2):119–126.
   PubMed Web of Science ®Google Scholar
• Guy W, NIMH. R Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. Rockville: NIMH; 1976.
   Google Scholar
• The Research Units on Pediatric Psychopharmacology Anxiety Study Group G The pediatric anxiety rating scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1061–1069.
   PubMed Web of Science ®Google Scholar
• Beidel DC, Turner SM, Morris TL. A new inventory to assess childhood social anxiety and phobia: the social phobia and anxiety inventory for children. Psychol Assess. 1995;7(1):73–79.
   Web of Science ®Google Scholar
• March JS, Parker JD, Sullivan K, et al. The multidimensional anxiety scale for children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(4):554–565.
   PubMed Web of Science ®Google Scholar
• La Greca A. Manual for social anxiety scales for children and adolescents. Coral Gables. FI: University of Miami; 1998.
   Google Scholar
• Maier W, Buller R, Philipp M, et al. The Hamilton anxiety scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14(1):61–68.
   PubMed Web of Science ®Google Scholar
• Masia-Warner C, Storch EA, Pincus DB, et al. The Liebowitz social anxiety scale for children and adolescents: an initial psychometric investigation. J Am Acad Child Adolesc Psychiatry. 2003;42(9):1076–1084.
   PubMed Web of Science ®Google Scholar
• Schünemann HJ, Oxman AD, Vist GE, et al. Interpreting results and drawing conclusions. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Ltd; p. 359–387.
   Google Scholar
• Higgins JPT, Savović J, Page MJ, Sterne JAC on behalf of the RoB2 Development Group Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) (2019). [cited 2019 Mar 25]. Available from: www.riskofbias.info.
   Google Scholar
• da Costa CZG, de Morais RMCB, Zanetta DMT, et al. Comparison among clomipramine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol. 2013;23(10):687–692.
   PubMed Web of Science ®Google Scholar
• Beidel DC, Turner SM, Sallee FR, et al. SET-C VERSUS fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1622–1632. doi:10.1097/chi.0b013e318154bb57.
   PubMed Web of Science ®Google Scholar